The trial of several second‐generation CDK9 inhibitors such as BAY1143572 (NCT01938638), BAY1251152 (NCT02635672) and AZD4573 (NCT03263637) in patients with haematological malignancies which frequently exhibit a dependency on c‐Myc, such as multiple myeloma and diffuse large B‐cell lymphoma, further highlights the clinical potential of targeting CDK9 in Myc‐driven cancers [55, 57]. Here, CDK9 is linked to cancer.